2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Author: kieran
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors
Cancer Immunology Research
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies
Cell Reports Medicine
LAVA-051, a novel bispecific gamma-delta T-cell engager (Gammabody™), in relapsed/refractory MM and CLL: pharmacodynamic and early clinical data
Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager, confirmed in the clinical setting
Submitted for presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
Frontiers in Immunology publication, Saura-Esteller, et al.
Phase I dose escalation of LAVA-051, a novel bispecific γδ-T cell engager (Gammabody™), in relapsed/refractory hematological malignancies
European Hematological Association (EHA) 2022 Congress presentation Broijl, et al.
Phase I dose escalation of LAVA-051, a novel bispecific gamma delta T-cell engager (Gammabody™), in relapsed/refractory hematological malignancies
2022 American Society of Clinical Oncology (ASCO) Annual Meeting presentation
Brojil, et al.
A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia (Clinical Cancer Research)
Although considerable progress has been made with autologous T cell–based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity that is of particular concern in the elderly CLL population. Vγ9Vδ2-T cells form a conserved T-cell subset with strong intrinsic immunotherapeutic potential, largely because of their capacity to be triggered by phosphoantigens that can be overproduced by CLL and other malignant cells. Specific activation of Vγ9Vδ2-T cells by a bispecific antibody may improve the efficacy and toxicity of autologous T-cell–based therapy in CLL. Link to full article